British Journal of Urology · 2011 · 17 citations · 12 references
MedicineOncologyUrologyGenitourinary OncologyUrologic OncologyUrologic SurgeryBladder CancerGenitourinary Cancer PharmacotherapyInterferon-based TherapyInterferon Alpha-2b Therapy
Study Type – Therapy (individual cohort) Level of Evidence 2b What’s known on the subject? and What does the study add? BCG is the standard treatment for superficial bladder cancer. The combination of BCG and interferon‐alfa may be more effective and less toxic than BCG alone. With long term follow up the efficacy and toxicity of combined intravesical BCG and interferon‐α and BCG alone seems to be equal in treatment of superficial bladder cancer. OBJECTIVE • To evaluate the efficacy and toxicity of the combination of bacillus Calmette‐Guérin (BCG) and interferon α‐2B (IFNα‐2B) in treating superficial bladder cancer (SBC). The mentioned combination has shown synergism in pre‐clinical studies. PATIENTS AND METHODS • The present study is a single‐arm, open‐label, single‐institution prospective trial. Patients with Ta, T1 or in situ carcinoma and no previous intravesical therapy were included between July 2002 and June 2009. • Patients were treated with weekly intravesical instillation of 27 mg of BCG mixed with 10 million units (MU) of IFNα‐2B for six consecutive weeks followed by 3‐weekly booster instillations at 3 months if there was no recurrence. • The primary endpoint was disease recurrence. Secondary endpoints were disease progression and toxicity. • Patients were followed‐up with cystoscopy and urine cytology every 3 months. RESULTS • In all, 50 patients were included. • At a median follow‐up of 55.8 months, 31 (62%) patients were recurrence‐free. • Progression to muscle invasion occurred in two (4%) and metastasis occurred in two (4%) patients. • Treatment was well tolerated, with grade III dysuria and frequency occurring in 18 and 14% of patients, respectively, and with 74% of patients being able to complete the maintenance dosage. CONCLUSION • The combination of BCG and IFNα‐2B in the patient population with SBC has similar efficacy and toxicity to BCG monotherapy.
12
T. Tong, S. Bolden, P. A. Wingo · CA A Cancer Journal for Clinicians · 1997 · 2K citations · Full text
Donald L. Lamm, Brent A. Blumenstein, E. David Crawford et al. · New England Journal of Medicine · 1991 · 617 citations · Full text
Harry W. Herr, David M. Schwalb, Zuo‐Feng Zhang et al. · Journal of Clinical Oncology · 1995 · 303 citations
Fadi N. Joudi, Michael A. O’Donnell · Urologic Oncology Seminars and Original Investigations · 2006 · 243 citations